Cancer-selective gene therapy company Tocagen has become the third company to get accepted on the European Medicines Agency’s priority medicines (PRIME) scheme for an investigational drug for brain cancer.
Tocagen’s advanced therapy product, Toca 511 (vocimagene amiretrorepvec), was granted a place on the scheme for the treatment of high...







